Se ha descubierto que las atmósferas de planetas en sistemas solares a distancias de hasta 160 años-luz de una supernova pueden sufrir daños graves, capaces de comprometer la habitabilidad de tales mundos, debido a una fase hasta ahora desconocida del proceso de explosión …
Las supernovas son más peligrosas de lo creído para los planetas de su región galáctica Read More »
AlzeCure Pharma AB a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company arranges a Capital Markets Day on May 17 at 10:00-11:30 CET with Professor Bengt Winblad as an invited guest speaker.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2023 and provided an update on clinical and corporate developments.
Apyx Medical Corporation today reported financial results for its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023.
Noticias de la actualidad científica y tecnológica del 8 de mayo de 2023. …
Mirum Pharmaceuticals, Inc. announced that on May 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,850 shares of common stock and 10,430 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.
Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.
Takeda announced strong financial results for fiscal year 2022, delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products.
Innovent Biologics, Inc. announced that the phase 2 clinical study of higher dose mazdutide in Chinese adults with obesity achieved the 24-week primary endpoint.
